Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.
about
Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor bindingA fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors.Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway.An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion.A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain.Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics.Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum.Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potencyA fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses.Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HRole for the terminal clasp of HIV-1 gp41 glycoprotein in the initiation of membrane fusionTrimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathwaysSwapped-domain constructs of the glycoprotein-41 ectodomain are potent inhibitors of HIV infectionReceptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer.Selection of T1249-resistant human immunodeficiency virus type 1 variants.Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.Recent progress in antiretrovirals--lessons from resistanceInteractions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coilCommon principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm.Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.Mutations in the feline immunodeficiency virus envelope glycoprotein confer resistance to a dominant-negative fragment of Tsg101 by enhancing infectivity and cell-to-cell virus transmission.Amphipathic properties of HIV-1 gp41 fusion inhibitors.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors."Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches.Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant.Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein.The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region.AAFreqCoil: a new classifier to distinguish parallel dimeric and trimeric coiled coils.The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment.The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype.Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formationKinetic dependence to HIV-1 entry inhibition.Trimeric membrane-anchored gp41 inhibits HIV membrane fusion.HIV vs. HIV: Turning HIV-Derived Peptides into Drugs
P2860
Q28471980-EBFBC7A0-2F76-4214-85A2-1F90F5C7A2CFQ33239507-4FD2D6AC-BABC-45A6-9DD6-498D9B45C1D2Q33282526-1CE0535D-626D-4576-B4F2-06181D172440Q33429777-3E861247-0540-4B7C-BEDE-5E8EEAF2DA99Q33504556-5D972EDC-E555-47DA-9CC4-34333643EBDEQ33758760-55F603BA-2BC1-4170-A88C-BE5336A8A0A8Q33877501-E167C737-F9A0-41F8-8901-63E66ACEF256Q33966639-A00C5DCE-BF52-4470-B7EB-03659C62978CQ34225654-2FF1D227-50EE-41D1-B20F-3563CEA1D15AQ34281656-3D36848F-A629-4DA1-82B9-2D03AF97E8E6Q34310045-39B21204-E585-4334-8CD1-3A716584A47CQ34778515-ADC09CEC-9AF7-4C37-AF73-1273468E2956Q34800822-2D9CAA8E-4CB0-45E9-A319-9A3DC52149B4Q34999859-98EF2AED-1BF4-40B7-B8A3-59C51AC86D3BQ35599288-EEEAB28C-02AB-4B34-924D-28BA5ADEA2DFQ35842116-62A505ED-729C-477F-A6D2-00721996D0AAQ35868288-0EA4AFB6-1A5E-44E5-B16B-32135B3EA7B1Q36036157-B1D996FC-E7A4-42C3-8149-F1717174A8A1Q36228646-1722A1DC-778B-4FFB-940C-60A00091DE7AQ36748009-EDB0CC2A-A9FF-4440-A34E-06699D7A140AQ36954635-9C4BEDA9-86AC-49A3-890D-1765FC11A8BFQ36967857-CC1CFDD6-CEDB-49BB-8E5D-0A7F0EAC6FB1Q37081918-774AC72B-0B2F-4220-991A-5B509B1DD569Q37348882-4168677B-89FF-48FE-AA5C-299FE7D14858Q37596642-68287FC5-2DE0-4B07-876A-1DA323F129BAQ37619606-BCF417E9-1B3F-4A1D-A843-0C2D58BBB608Q37951610-121E8494-6160-460A-AAF4-436EE71050E8Q38076139-597DB887-78BB-4F0E-A837-95DC65D3BD52Q38684463-008EE132-3117-4B22-973E-01B69E274474Q39152233-80872E8F-94C9-4A0A-986B-79F71ABD2273Q39982324-042AE89E-54B5-41BC-8A36-8EB4573808F4Q40203143-9A190C9B-7D0B-4F4E-9586-B2224D9E6CA6Q40387378-1EC958F8-6D47-48A5-890C-357C406C9F8CQ41006080-28DE53F9-5FFD-4F95-8549-7BBEDAD08846Q41345703-1F2E35BB-4242-4F2D-84D3-761ED36AAC80Q42066659-5C2FA34E-D9BC-4CA3-A59D-14DFDF63D17EQ42180923-5A319FF4-F2B8-4DEE-B87D-85BF787E3298Q43627216-22EB0FE3-7DAB-4E42-9DEA-C8911A1D44D6Q43932246-9750742D-1270-46D9-A7AD-D79040558530Q58626543-02B4D728-09B1-4F04-AD22-8F9388EA47C3
P2860
Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Direct evidence that C-peptide ...... ptor-activated viral envelope.
@ast
Direct evidence that C-peptide ...... ptor-activated viral envelope.
@en
type
label
Direct evidence that C-peptide ...... ptor-activated viral envelope.
@ast
Direct evidence that C-peptide ...... ptor-activated viral envelope.
@en
prefLabel
Direct evidence that C-peptide ...... ptor-activated viral envelope.
@ast
Direct evidence that C-peptide ...... ptor-activated viral envelope.
@en
P2093
P2860
P1433
P1476
Direct evidence that C-peptide ...... ptor-activated viral envelope.
@en
P2093
Carl T Wild
Graham P Allaway
Karl Salzwedel
Mary Reddick
Nicole R Kilgore
P2860
P304
P356
10.1128/JVI.77.13.7669-7672.2003
P407
P577
2003-07-01T00:00:00Z